EP2809311A1 - Formulations de comprimés effervescents contenant la combinaison voglibose et metformine - Google Patents

Formulations de comprimés effervescents contenant la combinaison voglibose et metformine

Info

Publication number
EP2809311A1
EP2809311A1 EP13714364.0A EP13714364A EP2809311A1 EP 2809311 A1 EP2809311 A1 EP 2809311A1 EP 13714364 A EP13714364 A EP 13714364A EP 2809311 A1 EP2809311 A1 EP 2809311A1
Authority
EP
European Patent Office
Prior art keywords
effervescent
formulation
range
formulation according
citric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13714364.0A
Other languages
German (de)
English (en)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2809311A1 publication Critical patent/EP2809311A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)

Definitions

  • the present invention relates to pharmaceutical formulations comprising voglibose and metformin that shall be used in the treatment of diabetes.
  • Voglibose was first disclosed in the application numbered EP0056194 (Bl).
  • the a-glucosidase inhibitor voglibose is effective in slowing carbohydrate metabolism, in removing hyperglycaemic symptoms and in the treatment of patients with metabolic disorders and it has a role in prevention of high blood sugar level and it is used in the treatment of diabetes.
  • Metformin on the other hand, was first disclosed in the application numbered US3174901 (A). In said document, it was disclosed that metformin is effective in the treatment of diabetes.
  • Metformin is available in 500, 850, 1000 mg film coated tablet forms on the market.
  • an alpha glucosidase inhibitor voglibose prevents digestion of polysaccharides and due to undigested polysaccharides in the intestine, flatulence, diarrhea and similar digestive system complaints are frequently observed in the patients.
  • the present invention relates to effervescent tablet formulations comprising voglibose and metformin hydrochloride as the active agent.
  • the present invention relates to effervescent formulations comprising voglibose-metformin hydrochloride combination, effervescent couple comprising at least one effervescent acid and at least one effervescent base and at least one pharmaceutically acceptable excipient.
  • the present invention relates to selection of effervescent acid and base constituting the effervescent couple from a specific group of substances for the effervescent tablet formulations comprising voglibose-metformin hydrochloride combination.
  • At least one pharmaceutically acceptable effervescent acid that can be used in said voglibose- metformin hydrochloride formulations is selected from a group comprising organic acids such as malic acid, citric acid, tartaric acid, fumaric acid.
  • physico-chemical parameters such as tablet dispersion time and tablet hardness vary according to the excipients and their amounts used in the effervescent tablet formulations.
  • the dosage forms obtained may crumble quickly and be broken during packaging, storing and carrying.
  • Hard tablets on the other hand, take long to dissolve. Long dissolution time is an important problem especially for formulations in effervescent form.
  • the effervescent couple comprising citric acid as the effervescent acid and an effervescent base selected from a specific group of effervescent bases provides said physico-chemical characteristics.
  • the present invention relates to effervescent tablet formulations comprising voglibose-metformin hydrochloride combination and effervescent couple that is composed of citric acid as the effervescent acid and an effervescent base selected from a specific group of effervescent bases.
  • At least one pharmaceutically acceptable effervescent base that can be used in said voglibose- metformin hydrochloride formulations is selected from a group comprising sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate.
  • the effervescent base is preferably selected from bicarbonates; preferably it is potassium hydrogen carbonate.
  • the inventors have obtained ideal tablet dispersion time and hardness by using citric acid in the range of 30 to 55%, preferably in the range of 35 to 50% in proportion to weight of unit formulation in the effervescent tablet formulations comprising voglibose-metformin hydrochloride combination.
  • a characteristic feature of the present invention relates to effervescent tablet formulations comprising voglibose-metformin hydrochloride combination wherein citric acid is used in the range of 30 to 55%, preferably in the range of 35 to 50% in proportion to weight of unit formulation.
  • the moisture ratio of citric acid that shall be used in the formulations of the present invention varies in the range of 0.01% to 0.3%, preferably in the range of 0.05 to 01%.
  • the hardness of the tablets obtained from said formulations varies in the range of 3 to 15 kP, preferably in the range of 5 to 10 kP. It was observed that effervescent tablets comprising voglibose and metformin hydrochloride having said hardness value are durable under abrasive conditions such as carrying, production, etc. as well as they can disperse in a short time.
  • the inventors have obtained a pharmaceutical mixture that can remain homogeneous during production and also disperse in a short time, for instance in less than 5 minutes by using effervescent acid having a specific particle size in said effervescent tablet formulations.
  • citric acid having a dso value in the range of 100 to 250 ⁇ , preferably in the range of 150 to 200 ⁇ and a d9 0 value in the range of 280 to 380 ⁇ , preferably in the range of 300 to 350 ⁇ has a positive effect on dispersion of the formulation.
  • d 5 o signifies that half of the said substance by volume has a particle size over the value stated with d 50 and other half of the substance has a particle size below the value stated with d5o.
  • d ⁇ signifies that 90% of the said substance by volume has a particle size below the value stated with dgo and 10% of the substance has a particle size over the value stated with d 0.
  • D50 and dgs values can be measured with one of the known measuring devices, for instance with a device which measures particle distribution by laser diffraction (for instance, Malvern Mastersizer etc.).
  • the present invention relates to effervescent tablet formulations comprising voglibose-metformin hydrochloride combination, wherein citric acid having a d 5 o value in the range of 100 to 250 ⁇ , preferably in the range of 150 to 200 ⁇ and a dcio value in the range of 280 to 380 ⁇ , preferably in the range of 300 to 350 ⁇ and a moisture ratio in the range of 0.01% to 0.3%, preferably in the range of 0.05% to 0.1%, is used in the range of 30 to 55%, preferably in the range of 35 to 50% in proportion to total weight of unit formulation.
  • the ratio of the effervescent base to citric acid constituting the effervescent couple is in the range of 1:1 to 1 :3, preferably in the range of 1:1.5 to 1 :2.
  • At least one pharmaceutically acceptable excipient that can be used in addition to effervescent couple in voglibose-metformin formulations of the present invention can be selected from a group comprising diluent, binder, lubricant, flavouring agent and glidant.
  • the diluent that can be used in said formulations is selected from a group comprising calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, microcrystalline cellulose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, mannitol, simethicone, sorbitol, starch, sodium chloride, sucrose, talc, xylitol.
  • the binder that can be used in said formulations can be selected from a group comprising carboxymethyl cellulose sodium, ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminium silicate, maltodextrin, methylcellulose, povidone, starch.
  • the lubricant that can be used in said formulations can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulphate, talc, stearic acid, zinc stearate.
  • the flavouring agent that can be used in said formulations can be selected from blackberry, menthol, lemon, orange, vanilla, strawberry, raspberry, caramel and similar flavours.
  • the glidant that can be used in said formulations is selected from a group comprising tribasic calcium phosphate, colloidal silicone dioxide, magnesium silicate, magnesium trisilicate, talc.
  • the formulations of the present invention are preferably prepared by wet granulation method.
  • wet granulation method two active agents are mixed with the excipients for a length of time.
  • the mixture obtained is granulated with the granulation solution and the granules are dried. After this phase, the diluent and the lubricant are added and mixed again.
  • the mixture obtained is compressed in tablet form and packaged.
  • Example 1 Formulation for Preparation of Effervescent Tablets Comprising Voglibose and Metformin.
  • excipients 3.490 The formulation given above is prepared by wet granulation method. Firstly, the effervescent couple and the active agents are mixed. The granulation solution comprising at least one excipient and water is added into this solution. The mixture obtained is dried. The granules obtained are sieved and mixed with the other excipients. In the last step, tablet compression and packaging processes are realized.
  • Example 2 Formulation for Preparation of Effervescent Sachets Comprising Voglibose and Metformin.
  • the formulation given above is prepared by wet granulation method. Firstly, the effervescent couple and active agents are mixed. The granulation solution comprising at least one excipient and water is added into this mixture. The mixture obtained is dried. The granules obtained are sieved and mixed with the other excipients. The formulation obtained is filled into sachets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des formulations effervescentes contenant la combinaison voglibose-chlorhydrate de metformine, un couple effervescent comprenant au moins un acide effervescent et au moins une base effervescente, et au moins un excipient pharmaceutiquement acceptable.
EP13714364.0A 2012-01-31 2013-01-31 Formulations de comprimés effervescents contenant la combinaison voglibose et metformine Withdrawn EP2809311A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201201094 2012-01-31
PCT/TR2013/000052 WO2013115743A1 (fr) 2012-01-31 2013-01-31 Formulations de comprimés effervescents contenant la combinaison voglibose et metformine

Publications (1)

Publication Number Publication Date
EP2809311A1 true EP2809311A1 (fr) 2014-12-10

Family

ID=48048164

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13714364.0A Withdrawn EP2809311A1 (fr) 2012-01-31 2013-01-31 Formulations de comprimés effervescents contenant la combinaison voglibose et metformine

Country Status (2)

Country Link
EP (1) EP2809311A1 (fr)
WO (1) WO2013115743A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014322810A1 (en) * 2013-09-21 2016-02-11 Effrx Pharmaceuticals Sa Low-sodium effervescent pharmaceutical formulations
GB201520007D0 (en) * 2015-11-12 2015-12-30 Sensidose Ab Compacted powder
TR201914043A1 (tr) * 2019-09-16 2021-04-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapagli̇flozi̇n ve metformi̇n i̇çeren efervesan tablet formülasyonlari

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE3166093D1 (en) 1981-01-05 1984-10-18 Takeda Chemical Industries Ltd N-substituted pseudo-aminosugars, their production and use
IE59106B1 (en) * 1985-05-31 1994-01-12 Warner Lambert Co A therapeutic effervescent composition and a method of preparing the same
CA2009326C (fr) * 1989-05-09 1998-01-27 Lawrence J. Daher Solution pour granulation aqueuse et methode pour granulation de tablettes
CN101590007A (zh) * 2008-05-27 2009-12-02 北京瑞伊人科技发展有限公司 一种盐酸二甲双胍/伏格列波糖降糖口服制剂组合物及其制备
TR201000688A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013115743A1 *

Also Published As

Publication number Publication date
WO2013115743A1 (fr) 2013-08-08

Similar Documents

Publication Publication Date Title
JP5421775B2 (ja) オキシコドンを含む顆粒及び口腔内崩壊錠剤
EP2588086B1 (fr) Compositions pharmaceutiques comprenant du lactate de 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoline-2-one monohydraté
EP2893940A2 (fr) Matière granulée pour un comprimé qui se désintègre rapidement dans la bouche
CN113018273B (zh) 一种固体制剂及其制备方法和用途
EP2745848B1 (fr) Comprimé à désintégration par voie orale contenant des particules fines d'hydroxyalkyl cellulose
WO2013115743A1 (fr) Formulations de comprimés effervescents contenant la combinaison voglibose et metformine
US20150141520A1 (en) Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof
EP2848242A1 (fr) Formulations orodispersibles de Linagliptin
WO2013115746A1 (fr) Procédé de préparation de compositions pharmaceutiques (effervescentes) contenant un inhibiteur de l'apha-glucosidase (miglitol) et de la metformine
EP2826465B1 (fr) Formulations de comprimé à désintégration orale de donépézil
US9675551B2 (en) Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
WO2015008825A1 (fr) Comprimé à désintégration orale
EP1539148A2 (fr) Preparation de bicifadine
RU2616263C2 (ru) Таблетка с замедленным высвобождением, содержащая леводропропизин, и способ ее изготовления
WO2014104989A1 (fr) Compositions pharmaceutiques comprenant de l'aripiprazole
WO2013115738A1 (fr) Acarbose micronisée
WO2013077819A1 (fr) Préparations pharmaceutiques comprenant du natéglinide
TW200948398A (en) Vancomycin hydrochloride tablet
WO2014007775A1 (fr) Nouvelle formulation à dissolution rapide
EP2976067B1 (fr) Composition pharmaceutique comprenant un agent antibactérien de fluoroquinolone et son procédé de préparation
CN110227067B (zh) 一种盐酸普拉克索缓释片及其制备方法
JP2018048136A (ja) 錠剤およびその製造方法
Patel et al. Formulation development and evaluation of diltiazem hydrochloride gastro retentive floating tablets
WO2014192022A1 (fr) Compositions pharmaceutiques de rasagiline
WO2014035355A1 (fr) Combinaisons pharmaceutiques comprenant un agent actif dérivé de la quinone

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140718

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160608

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161220